pharmaceutical composition, prophylactic agent or therapeutic agent, agents for improving the function of B cells in the pancreas, and for reducing the ratio of glycosylated hemoglobin, and, uses of 5- 4- (6-methoxy-1-methyl-1h- benzimidazol-2-ylmethoxy) benzyl thiazolidine-2,4-dione or a pharmaceutically acceptable salt thereof and a phasease inhibitor, and 2-amino-5-isobutyl-4- 2- 5- ( n, n'-bis ((s) -1ethoxycarbonyl) ethyl) phosphonamido furanyl} thiazole or a pharmacologically acceptable salt thereof

摘要

PHARMACEUTICAL COMPOSITION, PROPHYLATIC AGENT OR THERAPEUTIC AGENT, AGENTS FOR IMPROVING B-CELL FUNCTION IN THE Pancreas, AND FOR THE REDUCTION OF Glycosylated HEMOGLOBIN, AND USES OF 5- [4--1H-METHYL BENZIMIDAZOL-2-ILMETTAXI) BENZYL] TIAZOLIDINE-2,4-DIO IN OR OF A PHARMACOLOGICALLY ACCEPTABLE SALT OF THE SAME AND A FBPASE INHIBITOR, AND 2-AMINO-5-ISOBUTIL-4- {2- [5- ( N, N'-bis ((S) -1-ethoxycarbonyl) ethyl) phosphonamide] furanyl thiazole or a pharmaceutically acceptable salt thereof. To provide a treatment process for diabetes mellitus that has excellent decreasing activity in blood glucose levels and improve the effects on pancreatic 225 cell dysfunction in patients with diabetes mellitus. A pharmaceutical composition comprises an FBPase inhibitor and an insulin sensitizer which is 5- [4- (6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy) benzylthiazolidine-2,4-dione or a pharmacologically salt acceptable of it.